Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Suspended 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Burkitt Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Biphenotypic, Acute 1Down Syndrome 1

Interventions

Rituximab 18Cyclophosphamide 18Prednisone 12Doxorubicin 12Vincristine 9Lenalidomide 7ibrutinib 6obinutuzumab 5glofitamab 5Magnetic Resonance Spectroscopy 5polatuzumab vedotin 4fludarabine 4Prednisolone 4Oxaliplatin 4Gemcitabine 4Etoposide 4Cyclosporine 4venetoclax 3pembrolizumab 3fludarabine phosphate 3Whole-Body Irradiation 3Specimen Handling 3R-CHOP protocol 3Mycophenolic Acid 3Biopsy 3zanubrutinib 2prednylidene 2deltacortene 2acalabrutinib 2Sirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × prednylidene × 30 days × Clear all
NCT04850495 2026-06-04

Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Suspended
38 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03984448 2026-05-29

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
363 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡